<div id="readability-page-1"><p><span>Canopy Growth (NASDAQ:CGC - Get Free Report)</span> was downgraded by analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note issued on Saturday.</p><div><p><span></span><span>Get <strong>Canopy Growth</strong> alerts:</span></p></div><ul><li>The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock Valuations</li></ul><p>A number of other brokerages have also commented on CGC. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Canopy Growth in a report on Wednesday, January 21st. Benchmark raised Canopy Growth from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, November 10th. Finally, Alliance Global Partners  reiterated a &#34;neutral&#34; rating on shares of Canopy Growth in a research note on Saturday. Three analysts have rated the stock with a Hold rating and two have assigned  a Sell rating to the company. According to MarketBeat, Canopy Growth  has an average rating of &#34;Reduce&#34;.</p><p><b>Check Out Our Latest Stock Report on Canopy Growth</b></p><h2>Canopy Growth Stock Up 1.9%</h2><ul><li>Constellation Brands: A Fallen Star or a Hidden Value Play?</li></ul><p>Shares of NASDAQ CGC opened at $1.10 on Friday. The company has a quick ratio of 4.23, a current ratio of 5.50 and a debt-to-equity ratio of 0.31. The firm has a market cap of $405.31 million, a PE ratio of -0.56 and a beta of 0.56. The company's fifty day simple moving average is $1.25 and its 200 day simple moving average is $1.29. Canopy Growth has a 12-month low of $0.77 and a 12-month high of $2.38. </p><p>Canopy Growth (NASDAQ:CGC - Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.10. Canopy Growth had a negative net margin of 113.21% and a negative return on equity of 61.97%. The business had revenue of $47.86 million during the quarter, compared to analyst estimates of $71.82 million.  As a group, sell-side analysts forecast that  Canopy Growth will post -2.81 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><ul><li>Profit from the Green Wave: Top Cannabis Stocks to Watch</li></ul><p>A number of institutional investors and hedge funds have recently bought and sold shares of CGC. TD Asset Management Inc lifted its holdings in  Canopy Growth by 58.5% in the 2nd quarter. TD Asset Management Inc now owns 178,719 shares of the company's stock worth $220,000 after purchasing an additional 65,998 shares in the last quarter.  Wealth Enhancement Advisory Services LLC raised its position in shares of  Canopy Growth by 81.3% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 32,336 shares of the company's stock valued at $41,000 after buying an additional 14,498 shares during the last quarter.  SBI Securities Co. Ltd. raised its position in shares of  Canopy Growth by 47.6% during the second quarter. SBI Securities Co. Ltd. now owns 532,541 shares of the company's stock valued at $650,000 after buying an additional 171,803 shares during the last quarter.  Baader Bank Aktiengesellschaft lifted its holdings in shares of  Canopy Growth by 112.4% in the third quarter. Baader Bank Aktiengesellschaft now owns 275,090 shares of the company's stock worth $402,000 after buying an additional 145,547 shares in the last quarter.  Finally, Midwest Trust Co purchased a new position in  Canopy Growth during the third quarter valued at $31,000. 3.33% of the stock is currently owned by institutional investors. </p><h2>Key Headlines Impacting Canopy Growth</h2><p>Here are the key news stories impacting Canopy Growth this week:</p><ul>   <li><span>Positive Sentiment: </span>Management guided to positive adjusted EBITDA in fiscal 2027 and flagged the strategic MTL acquisition and expanded focus on European markets, which supports a clearer path to profitability and potential upside from international growth. <i></i><span>Canopy Growth signals positive adjusted EBITDA in fiscal 2027 amid MTL acquisition and expanding European focus</span></li>    <li><span>Positive Sentiment: </span>Revenue beat consensus and the company reported a narrower loss versus a year earlier, helped by cost-cutting measures—evidence that restructuring is improving operating performance even if GAAP EPS remains negative. <i></i><span>Canopy Growth posts mixed Q3 results, narrower loss amid ongoing cost cuts</span></li>    <li><span>Neutral Sentiment: </span>Management’s Q3 earnings call highlighted both growth initiatives and near-term challenges; investors will be watching execution on European expansion and integration of MTL for confirmation of the guidance. <i></i><span>Canopy Growth Corp (CGC) Q3 2026 Earnings Call Highlights: Navigating Growth and Challenges in ...</span></li>    <li><span>Neutral Sentiment: </span>Short-interest data reported is unreliable/zero in the note provided (shows 0 shares and NaN change); there’s no clear short-squeeze signal from that entry. (No actionable link available.)</li>    <li><span>Negative Sentiment: </span>EPS missed expectations (reported -$0.10 vs. consensus -$0.03), which is a near-term negative for sentiment and could limit multiple expansion until profitability trends are confirmed. <i></i><span>Canopy Growth Q3 earnings release and call transcript</span></li>    <li><span>Negative Sentiment: </span>Company continues to show negative margins and a weak ROE, underscoring that profits remain a multi-quarter target and leaving CGC vulnerable if revenue growth or cost programs stall. <i></i><span>Canopy Growth Corporation (CGC) Reports Q3 Loss, Tops Revenue Estimates</span></li> </ul><h2>Canopy Growth Company Profile</h2> (Get Free Report)<p>Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.  </p><p>The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.</p><h2>Read More</h2><ul><li>Five stocks we like better than Canopy Growth</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dD?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dD"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Canopy Growth Right Now?</h2><p>Before you consider Canopy Growth, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.</p><p>While Canopy Growth currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wall Street Zen has downgraded Canopy Growth (NASDAQ:CGC) from a "hold" to a "sell" rating. This follows a series of mixed ratings from other brokerages, with Weiss Ratings maintaining a "sell (e+)" and Benchmark upgrading to "hold." Canopy Growth's stock opened at $1.10, with a market cap of $405.31 million. The company reported a narrower loss in its latest quarterly earnings, but missed EPS expectations. Analysts forecast a challenging year ahead with an average rating of "Reduce."</p>

Wall Street Zen Downgrades Canopy Growth (NASDAQ:CGC) to Sell